Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.
about
Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate.Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells.Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
P2860
Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Benefits from pharmacological ...... inib for clinical development.
@en
Benefits from pharmacological ...... inib for clinical development.
@nl
type
label
Benefits from pharmacological ...... inib for clinical development.
@en
Benefits from pharmacological ...... inib for clinical development.
@nl
prefLabel
Benefits from pharmacological ...... inib for clinical development.
@en
Benefits from pharmacological ...... inib for clinical development.
@nl
P2093
P2860
P1476
Benefits from pharmacological ...... tinib for clinical development
@en
P2093
Camelia Colichi
Catherine Delbaldo
Chantal Dreyer
Eric Raymond
Marie-Paule Sablin
P2860
P304
P356
10.1517/17425255.2010.506872
P407
P577
2010-08-01T00:00:00Z